OPKO Health (OPK) Projected to Release Earnings on Monday

OPKO Health (NASDAQ:OPK) is expected to be announcing its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect OPKO Health to announce earnings of ($0.08) per share and revenue of $131.2330 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The business had revenue of $124.20 million during the quarter, compared to analyst estimates of $130.51 million. During the same period last year, the company earned ($0.10) earnings per share. OPKO Health’s quarterly revenue was down 17.1% compared to the same quarter last year. On average, analysts expect OPKO Health to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OPKO Health Stock Performance

Shares of NASDAQ OPK opened at $1.22 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. OPKO Health has a one year low of $0.98 and a one year high of $1.61. The business’s 50-day moving average price is $1.37 and its two-hundred day moving average price is $1.26. The company has a market capitalization of $921.21 million, a P/E ratio of -4.52 and a beta of 1.48.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. StoneX Group Inc. bought a new position in shares of OPKO Health in the 4th quarter valued at approximately $27,000. Zacks Investment Management bought a new stake in OPKO Health during the fourth quarter worth approximately $27,000. Cibc World Markets Corp bought a new stake in OPKO Health during the fourth quarter worth approximately $34,000. EP Wealth Advisors LLC acquired a new position in OPKO Health during the fourth quarter valued at approximately $37,000. Finally, Norges Bank acquired a new position in OPKO Health during the second quarter valued at approximately $52,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings raised shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Finally, Barrington Research lowered shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health presently has an average rating of “Reduce” and an average price target of $1.55.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.